273.20
price down icon0.73%   -2.00
after-market After Hours: 273.20
loading
Johnson Johnson stock is traded at $273.20, with a volume of 8.97M. It is down -0.73% in the last 24 hours and up +3.20% over the past month. Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
See More
Previous Close:
$275.20
Open:
$280
24h Volume:
8.97M
Relative Volume:
1.30
Market Cap:
$657.68B
Revenue:
$97.93B
Net Income/Loss:
$21.04B
P/E Ratio:
31.67
EPS:
8.6278
Net Cash Flow:
$17.80B
1W Performance:
+3.56%
1M Performance:
+3.20%
6M Performance:
+18.86%
1Y Performance:
+44.51%
1-Day Range:
Value
$273.13
$282.01
1-Week Range:
Value
$264.20
$282.01
52-Week Range:
Value
$184.66
$282.01

Johnson Johnson Stock (JNJ) Company Profile

Name
Name
Johnson Johnson
Name
Phone
732-524-2455
Name
Address
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ
Name
Employee
140,800
Name
Twitter
@jnjnews
Name
Next Earnings Date
null
Name
Latest SEC Filings
Name
JNJ's Discussions on Twitter

Compare JNJ vs LLY, ABBV, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
JNJ icon
JNJ
Johnson Johnson
273.20 657.68B 97.93B 21.04B 17.80B 8.6278
LLY icon
LLY
Lilly Eli Co
1,417.54 1.26T 72.25B 25.28B 10.37B 27.78
ABBV icon
ABBV
Abbvie Inc
294.89 521.11B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
149.52 368.89B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
160.79 303.67B 54.66B 13.58B 16.05B 7.0171

Johnson Johnson Stock (JNJ) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-21-26 Downgrade Erste Group Buy → Hold
Sep-02-26 Resumed UBS Buy
May-13-26 Upgrade Leerink Partners Market Perform → Outperform
Apr-08-26 Resumed TD Cowen Buy
Jan-28-26 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-13-25 Initiated Scotiabank Sector Outperform
Oct-20-25 Upgrade Daiwa Securities Neutral → Outperform
Oct-03-25 Upgrade Wells Fargo Equal Weight → Overweight
Sep-23-25 Upgrade Guggenheim Neutral → Buy
Jul-23-25 Upgrade Erste Group Hold → Buy
May-13-25 Downgrade Leerink Partners Outperform → Market Perform
Dec-10-24 Resumed BofA Securities Neutral
Nov-15-24 Initiated Wolfe Research Outperform
Jul-23-24 Downgrade Daiwa Securities Outperform → Neutral
May-30-24 Resumed Goldman Neutral
Apr-18-24 Upgrade HSBC Securities Hold → Buy
Dec-13-23 Downgrade Wells Fargo Overweight → Equal Weight
Dec-01-23 Upgrade UBS Neutral → Buy
Oct-05-23 Initiated RBC Capital Mkts Outperform
Sep-06-23 Initiated HSBC Securities Hold
May-30-23 Resumed Citigroup Buy
Mar-29-23 Initiated UBS Neutral
Mar-01-23 Initiated Guggenheim Neutral
Nov-18-22 Initiated Credit Suisse Neutral
Oct-18-22 Initiated Barclays Equal Weight
Oct-14-22 Reiterated BofA Securities Neutral
Jun-22-22 Initiated Daiwa Securities Outperform
May-23-22 Resumed SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Mar-16-22 Downgrade Bernstein Outperform → Mkt Perform
Mar-02-22 Resumed BofA Securities Neutral
Dec-17-21 Initiated Goldman Neutral
Dec-15-21 Reiterated Citigroup Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
May-28-21 Resumed Morgan Stanley Overweight
Apr-28-20 Downgrade UBS Buy → Neutral
Apr-22-20 Upgrade BofA/Merrill Neutral → Buy
Mar-05-20 Initiated Citigroup Buy
Dec-19-19 Upgrade Barclays Equal Weight → Overweight
Dec-17-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-20-19 Initiated Cantor Fitzgerald Overweight
Oct-16-19 Upgrade Atlantic Equities Underweight → Neutral
Oct-11-19 Upgrade Bernstein Mkt Perform → Outperform
Jul-12-19 Resumed Credit Suisse Outperform
May-28-19 Initiated Goldman Buy
Jan-23-19 Reiterated Barclays Equal Weight
Jul-12-18 Upgrade Goldman Sell → Neutral
Jun-27-18 Initiated Bernstein Mkt Perform
Apr-23-18 Reiterated Citigroup Neutral
Apr-18-18 Reiterated Stifel Hold
Jan-24-18 Reiterated Stifel Hold
Jan-12-18 Reiterated Wells Fargo Outperform
Jan-02-18 Downgrade JP Morgan Overweight → Neutral
Oct-18-17 Reiterated RBC Capital Mkts Outperform
Oct-18-17 Reiterated Stifel Hold
View All

Johnson Johnson Stock (JNJ) Latest News

pulisher
09:23 AM

JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4? - Zacks Investment Research

09:23 AM
pulisher
Oct 29, 2026

Johnson & Johnson (JNJ.HA) Seasonal Returns ChartYahoo Finance - Yahoo! Finance Canada

Oct 29, 2026
pulisher
Oct 29, 2026

Johnson & Johnson (JNJ) Seasonal returns chart - Yahoo Finance Singapore

Oct 29, 2026
pulisher
Oct 29, 2026

Johnson & Johnson (JNJ) Seasonal Returns ChartYahoo Finance - Yahoo! Finance Canada

Oct 29, 2026
pulisher
Oct 29, 2026

Johnson & Johnson (JNJ) Seasonal returns chart - Yahoo Finance Australia

Oct 29, 2026
pulisher
Oct 29, 2026

Does Johnson & Johnson (JNJ) Have A New Edge In Plaque Psoriasis? - Yahoo Finance

Oct 29, 2026
pulisher
Oct 29, 2026

Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher - 24/7 Wall St.

Oct 29, 2026
pulisher
Oct 29, 2026

Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool

Oct 29, 2026
pulisher
Oct 29, 2026

Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance

Oct 29, 2026
pulisher
Oct 29, 2026

Is Johnson & Johnson Stock a Good Fit For Your Portfolio Risk? - Trefis

Oct 29, 2026
pulisher
Oct 29, 2026

State Street Health Care SPDR (XLV) Adds Eli Lilly and Johnson & Johnson on Tuesday - Yahoo Finance UK

Oct 29, 2026
pulisher
Oct 29, 2026

3 Unstoppable S&P 500 Stocks to Buy Before October Ends - The Motley Fool

Oct 29, 2026
pulisher
Oct 29, 2026

Johnson & Johnson: Strong Q3 Growth, But 2027 Could Test Its Earnings (NYSE:JNJ) - Seeking Alpha

Oct 29, 2026
pulisher
Oct 28, 2026

Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Gross - The National Law Review

Oct 28, 2026
pulisher
Oct 28, 2026

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.

Oct 28, 2026
pulisher
Oct 28, 2026

Family history of heart disease drives 3 J&J scientists - Johnson & Johnson

Oct 28, 2026
pulisher
Oct 28, 2026

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery - Ophthalmology Times

Oct 28, 2026
pulisher
Oct 28, 2026

The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research

Oct 28, 2026
pulisher
Oct 27, 2026

Johnson & Johnson (JNJ) Stock Trades At A Discount Following Its 97% Run - Yahoo Finance

Oct 27, 2026
pulisher
Oct 27, 2026

4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research

Oct 27, 2026
pulisher
Oct 27, 2026

Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings - Zacks Investment Research

Oct 27, 2026
pulisher
Oct 27, 2026

Johnson & Johnson schedules business review for December 8 - Investing.com

Oct 27, 2026
pulisher
Oct 27, 2026

Johnson & Johnson schedules business review for December 8 By Investing.com - Investing.com Canada

Oct 27, 2026
pulisher
Oct 27, 2026

Johnson & Johnson to hold investor business review on Dec. 8 - StreetInsider

Oct 27, 2026
pulisher
Oct 27, 2026

Johnson & Johnson to Host Enterprise Business Review - Business Wire

Oct 27, 2026
pulisher
Oct 27, 2026

Johnson & Johnson (JNJ) Sees $34.7 Million in Net ETF Selling on Oct. 23 - Yahoo Finance

Oct 27, 2026
pulisher
Oct 27, 2026

Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)? - Zacks Investment Research

Oct 27, 2026
pulisher
Oct 27, 2026

What Will Decide Johnson & Johnson Stock Over The Next Six Months? - Trefis

Oct 27, 2026
pulisher
Oct 27, 2026

J&J allegedly fires its own HR manager over disability request - Human Resources Director

Oct 27, 2026
pulisher
Oct 27, 2026

Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters - The Motley Fool

Oct 27, 2026
pulisher
Oct 26, 2026

What Do Johnson & Johnson (JNJ) Cancer Trial Wins Mean For Its Stock? - Yahoo Finance

Oct 26, 2026
pulisher
Oct 26, 2026

J&J reports promising results in three cancer studies - NJBIZ

Oct 26, 2026
pulisher
Oct 26, 2026

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.

Oct 26, 2026
pulisher
Oct 26, 2026

Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? - The Motley Fool

Oct 26, 2026
pulisher
Oct 26, 2026

ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda - BioSpace

Oct 26, 2026
pulisher
Oct 26, 2026

2 Beaten-Down Healthcare Stocks to Buy and Hold for the Next Decade - The Motley Fool

Oct 26, 2026
pulisher
Oct 26, 2026

Which Healthcare ETF Is the Better Buy: State Street’s Pharma XPH or Simplify’s Mission-Driven PINK? - The Motley Fool

Oct 26, 2026
pulisher
Oct 26, 2026

J&J reports 75% tumor response rate with novel prostate cancer therapy - Seeking Alpha

Oct 26, 2026
pulisher
Oct 26, 2026

Which Healthcare ETF Is the Better Buy: iShares’ Global IXJ or First Trust’s Biotech FBT? - The Motley Fool

Oct 26, 2026
pulisher
Oct 26, 2026

Should You Invest in the iShares U.S. Healthcare ETF (IYH)? - Zacks Investment Research

Oct 26, 2026
pulisher
Oct 26, 2026

Smith & Nephew and Johnson & Johnson Fail to Merge Orthopedic Businesses - marketscreener.com

Oct 26, 2026
pulisher
Oct 26, 2026

Johnson & Johnson Won UK Approval for Its Psoriasis Pill. Here’s Where the Stock Could Go by 2030 - TIKR.com

Oct 26, 2026
pulisher
Oct 25, 2026

Johnson & Johnson Deepens Hong Kong Commitment with Strategic Partnership to Accelerate Healthcare Innovation - BioPharma APAC

Oct 25, 2026
pulisher
Oct 25, 2026

Johnson & Johnson Won UK Approval for Its Psoriasis Pill. Here’s Where the Stock Could Go by 2030 - Yahoo Finance

Oct 25, 2026
pulisher
Oct 25, 2026

Johnson & Johnson reports response rate for head, neck cancer treatment (JNJ:NYSE) - Seeking Alpha

Oct 25, 2026
pulisher
Oct 25, 2026

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer - GlobeNewswire Inc.

Oct 25, 2026
pulisher
Oct 25, 2026

ESMO: J&J exec says RIPTAC readout is ‘best data we’ve ever seen’ for a prostate cancer drug - Fierce Biotech

Oct 25, 2026
pulisher
Oct 25, 2026

Johnson & Johnson (JNJ) Reports 69% Tumor Response Rate for Prostate Cancer Drug - TipRanks

Oct 25, 2026
pulisher
Oct 24, 2026

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy? - The Motley Fool

Oct 24, 2026
pulisher
Oct 24, 2026

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool

Oct 24, 2026

Johnson Johnson Stock (JNJ) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Johnson Johnson Stock (JNJ) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Schmid Timothy
EVP, WW Chair, MedTech
Sep 02 '26
Sale
274.74
33,597
9,230,440
25,447
Schmid Timothy
Officer
Sep 02 '26
Proposed Sale
274.74
33,597
9,230,440
0
Taubert Jennifer L
EVP, WWC. Innovative Medicine
Aug 17 '26
Sale
263.36
15,000
3,950,400
194,451
Taubert Jennifer L
EVP, WWC. Innovative Medicine
Aug 17 '26
Option Exercise
115.67
15,000
1,735,050
209,451
Taubert Jennifer L
Officer
Aug 17 '26
Proposed Sale
263.36
15,000
3,950,418
0
Duato Joaquin
CEO and Chairman of the Board
Aug 13 '26
Option Exercise
115.67
123,291
14,261,070
399,258
Duato Joaquin
CEO and Chairman of the Board
Aug 13 '26
Sale
261.17
123,291
32,199,927
275,967
Duato Joaquin
Officer
Aug 13 '26
Proposed Sale
261.17
123,291
32,199,927
0
Forminard Elizabeth
EVP, Chief Legal Officer
Aug 06 '26
Option Exercise
131.94
9,344
1,232,847
32,912
Forminard Elizabeth
EVP, Chief Legal Officer
Aug 06 '26
Sale
257.00
15,918
4,090,960
16,994
$294.89
price up icon 1.41%
MRK MRK
$149.52
price up icon 2.18%
NVS NVS
$160.79
price down icon 0.19%
AZN AZN
$186.65
price up icon 7.02%
$466.01
price up icon 1.15%
$170.68
price up icon 3.06%
Cap:     |  Volume (24h):